GS UHL (Votrient pazopanib 400 mg)
Generic Name: pazopanib
Pill with imprint GS UHL is Yellow, Capsule-shape and has been identified as Votrient pazopanib 400 mg. It is supplied by GlaxoSmithKline.
Votrient is used in the treatment of renal cell carcinoma; soft tissue sarcoma and belongs to the drug class VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Votrient pazopanib 400 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for GS UHL
Votrient
- Generic Name:
- pazopanib
- Imprint:
- GS UHL
- Strength:
- pazopanib 400 mg
- Color:
- Yellow
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- VEGF/VEGFR inhibitors
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- GlaxoSmithKline
- National Drug Code (NDC):
More about Votrient (pazopanib)
- Votrient Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 61 Reviews – Add your own review/rating
- Drug class: VEGF/VEGFR inhibitors
Consumer resources
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2018 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
